Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
AdAlta Ltd
1ADAdAlta Limited, a clinical stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. AdAlta Limited has collaborative partnerships with GE Healthcare Technologies Inc to develop i-body enabled PET imaging agents for use in immuno-oncology; and Carina Biotech Pty Ltd to develop CAR-T cell therapies for solid tumor. The company was incorporated in 2006 and is based in Bundoora, Australia. Address: La Trobe Institute of Molecular Science, Bundoora, VIC, Australia, 3086
Analytics
Preço Alvo de Wall Street
–Rácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave 1AD
Análise de Dividendos 1AD
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos 1AD
Avaliação de ações 1AD
Relatório 1AD
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |